The synaptic protein abounds in the cerebrospinal fluid of AD patients and in those in the prodromal phase of the disease.
Researchers have generated the first atomic-level structure of γ-secretase. The new view revealed interactions between amino acid residues and the locations of familial Alzheimer’s disease mutations.
In a clinical trial, people who used the surgically implanted breathing-assist device died nearly a year sooner than those who used only an oxygen mask.
Can proteins in the cerebrospinal fluid help tell movement disorders apart and predict who will develop dementia?
Though BACE1 and γ-secretase appear to orchestrate axonal pathfinding, researchers doubt inhibitors or modulators of these proteases would cause side effects in people treated for AD.
Research uncovers subtle links between early development problems and some forms of dementia.
Variability still plagues CSF biomarker measurements, but automated systems offer hope of a diagnostic assay.
Scientists are coming to grips with how tau spreads, and what the consequences are for the brain.
The protein normally comes in long and short isoforms, which hang out in the cytoplasm and on the nuclear envelope, respectively.
Researchers report multiple benefits of aerobic exercise on brain function, including some hints it could slow tau pathology.
At the right intensity and treatment duration, aerobic exercise can sharpen thinking skills and improve brain function even in cognitively impaired people, say researchers.
Polythiophene compounds stabilized prions and prevented them from spreading through the brains of infected mice. Researchers predicted the compounds could work on Aβ and tau, too.
At AAIC, new data on three anti-Aβ antibodies reinforced a sense of hope that Aβ immunotherapy may yet work out. Challenges with each antibody notwithstanding, all four leading candidates, including crenezumab, are now in Phase 3.
TDP-43 spots and expunges "cryptic" exons, study says.
Tiny injuries to capillaries in white matter, and to cells in gray matter, have come to be the focus of new imaging measures being explored in early presymptomatic AD.